Get the Stockscreener App
1.71
27.61%
0.37
After Hours:
1.70
-0.01
-0.58%
An 2 Therapeutics Inc stock is traded at $1.71, with a volume of 1.54M.
It is up +27.61% in the last 24 hours and up +61.32% over the past month.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
See More
Previous Close:
$1.34
Open:
$1.32
24h Volume:
1.54M
Relative Volume:
13.19
Market Cap:
$46.86M
Revenue:
-
Net Income/Loss:
$-33.99M
P/E Ratio:
-1.5145
EPS:
-1.1291
Net Cash Flow:
$-29.87M
1W Performance:
+61.32%
1M Performance:
+61.32%
6M Performance:
+35.71%
1Y Performance:
+36.80%
1-Day Range:
$1.32
$1.79
1-Week Range:
$1.055
$1.79
52-Week Range:
$1.00
$1.79
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.71 | 36.72M | 0 | -33.99M | -29.87M | -1.1291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-03-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-02-24 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-13-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-12-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-12-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-12-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
View All
An 2 Therapeutics Inc Stock (ANTX) Latest News
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - Business Wire
Drug film BXCL501 eases opioid withdrawal in Columbia University study - Stock Titan
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
CAD-1005 Phase 2 data spur FDA EOP2 talks for Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces Phase 2 Results with - GlobeNewswire
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - Yahoo Finance
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - Yahoo Finance
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Insider Monkey
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide - Yahoo Finance
Gain Therapeutics, Inc Advances Parkinson's Treatment to Phase 2 - TradingView
Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - GlobeNewswire
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer - Business Wire
Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics
FDA lets Intellia resume MAGNITUDE-2 Phase 3 trial for ATTRv-PN - Stock Titan
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - Yahoo Finance
GSK enters agreement to acquire RAPT Therapeutics - GSK
Peering Into Aquestive Therapeutics Inc's Recent Short Interest - Benzinga
Viking Therapeutics Unveils Promising Phase 2 Clinical Success, Fuels Stock Surge - timothysykes.com
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 - BioSpace
Actuate Therapeutics IncReports Positive Phase 2 Trial Data For ElraglusibSEC Filing - TradingView
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity - Finviz
Sustained Therapeutics Reports Positive Phase 2 Results for Its Long-Acting Non-Opioid Medication for Chronic Pain - Yahoo Finance
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases - Business Wire
Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewswire
Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Finviz
Beam Therapeutics Inc. (BEAM) reports updated data from BEACON Phase 1/2 Trial of Ristoglogene - MSN
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Yahoo Finance
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PR Newswire
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Insider Monkey
Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer - GlobeNewswire
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer - Yahoo Finance
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas - PR Newswire
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - GlobeNewswire
Sionna Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with - The Manila Times
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):